LMNA Cardiomyopathy:Cell Biology and Genetics Meet Clinical Medicine
Disease Models & Mechanisms 4:562-568, Lu,J.T., et al, 2011
Left Ventricular Systolic Dysfunction and the Risk of Ischemic Stroke in a Multiethnic Population
Stroke 37:1715-1719,1637, Hays,A.G.,et al, 2006
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Hypotension and Cognitive Impairment
Neurol 57:1986-1992,1945, Zuccala,G.,et al, 2001
Stroke in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction
Neurol 54:288-294, Pullicini,P.M.,et al, 2000
Treatment of End Stage Dilated Cardiomyopathy
Br Heart J 72:S52-S56, O'Connell,J.B.,et al, 1996
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Severe Cardiac Failure in a Patient with Multiple Sclerosis Following Low-Dose Mitoxantrone Treatment
Neurol 73:991-993, D�rr,J.,et al, 2009
A Brewing Back Pain
NEJM 385:66-72, Pischel, L.,et al, 2021
Stroke Associated with Cardiac Surgery, Determinants, Timing, & Stroke Subtypes
Arch Neurol 54:83-87, Libman,R.B.,et al, 1997
Complications of Intravenous Immune Globulin Treatment in Neurologic Disease
Neurol 47:674-677, Brannagan III,T.H.,et al, 1996
Superior Sagittal Sinus Thrombosis
Arch Neurol 34:2, Gettelfinger,D.M.,et al, 1977